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Abstract
Introduction: Although the Minnesota Living with Heart Failure Questionnaire (MLHF-Q) is one of the most widely 
used tools to assess Health-Related Quality of Life (HRQoL) in patients with chronic heart failure (CHF), it has 
not been validated in Latin American Spanish-speaking populations. Objective: We evaluated internal consistency 
and construct validity of the MLHF-Q in patients with CHF from Colombia. Methods: The Spanish version of 
the MLHF-Q was given to 200 patients. Cronbach’s alpha was used to evaluate internal consistency. Confirmatory 
factorial Principal Component Analysis (PCA) and Rasch analysis were used to evaluate construct validity. The 
discriminative capacity was measured using the Mann-Whitney U test. Results: Median age was 64 years, 63% of 
the patients included in the study were men, and 79.5% had a left ventricular ejection fraction (LVEF) ≤ 45%. The 
median of the total score of HRQoL was 40 points (Q1=20; Q3=55), physical dimension 11 points (Q1=4; Q3=23) 
and emotional dimension 7 points (Q1=3; Q3=13). Global internal consistency of MLHF-Q was 0.91 (95% CI 
0.89 - 0.93). In the PCA, the three dimensions explained 47.7% and 54.0% in Rasch analysis, in which five items 
presented misfit. Worse HRQoL was observed among women than men in the emotional dimension (p=0.047). 
Discriminative capacity for the overall score of the MLHF-Q and their subscales was observed in age and New 
York Heart Association (NYHA) functional class (p<0.05). Conclusions: Our findings confirmed the three-factor 
structure of the MLHF-Q, and satisfactory level for internal consistency. Additionally, these results suggest that the 
questionnaire adequately reflects the severity of the disease. However, further studies are required to validate these 
findings in Colombian population and to evaluate the sensitivity to change of the MLHF-Q in longitudinal designs.
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Resumen
Introducción: El Minnesota Living with Heart Failure Questionnaire (MLHF-Q) es uno de los instrumentos más 
utilizados para medir la Calidad de Vida Relacionada con la Salud (CVRS) en pacientes con Falla cardíaca Crónica 
(FCC); sin embargo, éste no ha sido validado en poblaciones latinoamericanas hispanohablantes. Objetivo: Evaluar 
la consistencia interna y validez de constructo del MLHF-Q en pacientes con FCC de Colombia. Métodos: La 
versión en español del MLHF-Q fue diligenciada por 200 pacientes. La consistencia interna se evaluó con el Alpha 
de Cronbach. La validez de constructo fue examinada por dos métodos: Análisis de Componentes Principales 
(ACP) confirmatorio y análisis Rasch. Se evaluó la capacidad discriminativa del instrumento con la prueba U- 
Mann-Whitney. Resultados: Mediana de edad de 64 años, 63% hombres y el 79.5% de los participantes tenían 
fracción de eyección del ventrículo izquierdo (FEVI) ≤ 45%. La mediana del puntaje total de CVRS fue 40 puntos 
(Q1=20; Q3=55), dimensión física 11 puntos (Q1=4; Q3=23) y dimensión emocional 7 puntos (Q1=3; Q3=13). La 
consistencia interna fue 0.91 (IC 95% 0.89 - 0.93). En el ACP, las tres dimensiones explicaron el 54.0% y 47.7% en el 
análisis Rasch, en éste último cinco ítems presentaron desajuste. Se observó peor CVRS en mujeres que en hombres 
en la dimensión emocional (p=0.047) y se evidenció capacidad discriminativa de las subescalas y el puntaje total 
del MLHF-Q en la edad y la clase funcional New York Heart Association (NYHA) (p<0.05). Conclusión: Nuestros 
hallazgos confirmaron la estructura de tres factores del MLHF-Q y un nivel satisfactorio para la consistencia interna. 
Adicionalmente, estos resultados sugieren que el cuestionario refleja adecuadamente la gravedad de la enfermedad. 
Sin embargo, se requieren estudios adicionales en población colombiana para validar estos hallazgos y evaluar la 
sensibilidad al cambio del MLHF-Q en diseños longitudinales.
Palabras clave: Insuficiencia cardíaca, calidad de vida, estudios de validación.
Introduction
Chronic Heart Failure (CHF) prevalence is over 5.8 
million in the USA, and over 23 million worldwide1. 
In Latin America, estimated Heart Failure (HF) 
prevalence is 1% (95% CI, 0.1 to 2.7%) with 199 per 
100,000 person-year2. The hospital readmission rates 
of patients with HF are 33%, 28%, 31%, and 35% at 
3, 6, 12, and 24 to 60 months of follow-up (median 
duration of hospitalization of 7.0 days), with 1-year 
mortality rate of 24.5% (95% CI, 19.4 to 30.0%) and in-
hospital mortality of 11.7% (95% CI, 10.4 to 13.0%)2. 
Although mortality has decreased in CHF, the estimated 
survival rate is 50% and 10% at five and ten years after 
diagnosis3.
The burden of the disease in CHF involves several 
limitations in patients carrying out daily life activities, 
and affects health-related quality of life (HRQoL) 
more severely than other chronic diseases4. Several 
studies have shown that HRQoL of patients with HF 
is worse than the general population, or patients with 
other chronic diseases4,5. Furthermore, the decline 
in quality of life of HF patients is not temporary, 
but rather progressive over time6. Nevertheless, 
measuring HRQoL in HF remains a challenge, and 
despite the existence of several instruments (generic 
and disease-specific) for assessing HRQoL, no 
consensus has been achieved on which instrument 
would be most suitable7. 
The Minnesota Living with Heart Failure Questionnaire 
(MLHF-Q) is a disease-specific instrument, consisting 
of 21 items addressing a wide range of HRQoL and it 
is the most frequently used internationally. Since 1987, 
the MLHF-Q has been translated into more than 30 
languages, including Spanish8-13 and it is used as an 
outcome measure in multiple clinical trials showing the 
best psychometric properties as to validity, reliability 
and sensitivity to change14-17. 
Even though Spanish is spoken by 95% of Latin 
America’s population, Brazil, where Portuguese 
is spoken, is the only regional country where the 
MLHF-Q has been validated18, while Colombia has 
no data available on the evaluation of the reliability 
and validity of the MLHF-Q. Therefore, we aimed to 
evaluate the internal consistency and construct validity 
of the MLHF-Q in patients with CHF in Colombia.
Methods
Study population
A cross-sectional study was conducted between 
February and October 2015 in the Heart Failure and 
Heart Transplant Clinic of Cardiovascular Foundation 
in Floridablanca city, Santander-Colombia. We included 
patients if they (i) were 18 years old or older and (ii) 
had a confirmed HF medical diagnosis by a cardiologist. 
Patients with mental sphere alterations or communication 
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limitations were excluded. All patients gave written 
informed consent and the Research Ethic Committee of 
the institution approved the research protocol.
In calculating our sample size, care was taken to 
comply with the 10-patient-per-analized-item criterion 
considered adequate for factorial analysis19. The 
sample was selected in a non-probabilistic way; all 
patients were invited to participate consecutively by a 
previously trained nurse who conducted the interviews 
upon medical control appointments.   
Clinical screening
HRQoL was measured with the MLHF-Q11, a specific 
self-report instrument for CHF patients. HRQoL 
questionnaire is made up of 21 items graded by the 
patient using a 6-point Likert-type scale ranging from 
0 (no impairment) to 5 (very much impairment). 
The MLHF-Q groups the items in three dimensions: 
physical (8 items), emotional (5 items), and the overall 
score for HRQoL (21 items). Eight separate items, 
which do not assess a single construct or dimension of 
HRQoL, measure social and economic impairments of 
patients with HF and contribute to the overall score. The 
total score has a range between 0 and 105 points, the 
physical dimension (between 0 and 40), the emotional 
dimension (0 and 25) and the separate items on the 
socio-economic impairments (0 and 40). High scores 
on the MLHF-Q scale indicate impaired HRQoL. The 
MLHF-Q has a global internal consistency measured 
by Cronbach’s alpha of 0.94 (95% CI, 0.91 to 0.95) 
and general intraclass correlation coefficient of 0.84, 
characteristics that make it suitable for use17.  
Statistical analysis
Continuous variables are reported as median and 
quartiles (Q) unless stated otherwise, and categorical 
variables are presented as percentages. Internal 
consistency was evaluated through Cronbach’s alpha 
coefficient20. Kaiser-Meyer-Oklin’s (KMO) index and 
Bartlett’s test of sphericity were estimated to establish 
the pertinence of factorial analysis. KMO ≥0.7 was 
considered acceptable21,22. 
To evaluate construct validity of the questionnaire, two 
different approaches were used: first, the structure of 
the model originally proposed by Rector and Cohn8 was 
examined by means of confirmatory factorial principal 
component analysis (PCA). Dimensional structure was 
identified through varimax-type octagonal rotation, 
factor loading, and those ≥0.4 were considered 
acceptable13,23. Second, polytomous Rasch rating scale 
model was used to assess each specific questionnaire 
dimension according to the factorial structure proposed 
by literature24. Thus, the first step was to evaluate 
the functioning of rating scale categories. A clearly 
progressive level of difficulty across item categories 
was expected as a criterion of adequate function. We 
also examined the standardized (ZSTD) fit statistics of 
persons for whom a score between ±3 was expected. 
For dimensionality evaluation, which is a fundamental 
requirement for construct validity, we applied the 
following criteria: (i) mean square information-weighted 
statistic (infit) and the outlier-sensitive statistic (outfit), 
with values between 0.7 and 1.3 indicate a good fit (ii) 
PCA of the residuals25. Unidimensionality was violated 
if, besides the first factor, other factors had eigenvalues 
>3, and the local dependency was assessed through 
the item residual correlations where values >0.5 may 
indicate that the response to one item may be determined 
by another. To detect the presence of differential item 
functioning (DIF), which occurs when groups within 
the sample respond differently from an individual item; 
we compared distinct levels of the trait by sex and age 
group (≤65 vs. >65 years). A Welch’s t statistically 
significant (p<0.05), and a difficulty difference ≥0.5 
logits were considered evidence of uniform DIF. 
Finally, discriminative capacity of the questionnaire was 
assessed by its ability to differentiate among subgroups 
of patients with different levels of CHF severity, taking 
into account the following hypothesis: women, higher 
age, superior New York Heart Association (NYHA) 
functional class and Left Ventricular Ejection Fraction 
(LVEF) under 45% will have higher scores of the 
MLHF-Q, by using the Mann-Whitney U test. All 
statistical tests were two-sided and a p-value <0.05 was 
considered significant. Data were analyzed using Stata 
Statistical Software, version 14 and Winsteps 3.80.0. 
Results
Characteristics of the study population
The proportion of missing data was 0%. During 
recruitment period, two hundred CHF patients 
fulfilled the selection criteria, agreed to participate and 
completed the questionnaire. Median age of participants 
was 64 (Q1=53; Q3=73) years old, 63.0 % were men, 
79.5% had a LVEF ≤ 45%, and 24.0% subjects were 
in NYHA functional class III-IV. Sociodemographic 
and clinical characteristics of the study population are 
shown in Table 1. 
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Table 1. Sociodemographic and clinical characteristics of the 
study population (n=200). 
Variable n (%)
Age (years)a
Sex 
Men
Women
Socioeconomic status
Low
Medium
High
Education status
Less than high school
High school
Greater than high school
Marital status
Married/living in a free union
Widowers
Single
Divorced
Employment status
Unemployed
Employees 
Pensioner
Housewives
Students
Etiology of Chronic heart failure
Ischemic
Chagas disease
Idiopathic
Multifactorial
Hipertensive
Valvular
Other (congenital, viral, peripartum and others)
LVEF (%)
≤45
>45
Functional class NYHA
I-II
III-IV
Charlson comorbidity index
1
2
3
>3
Medications 
Beta-Blocker
ACE inhibitor
Angiotensin receptor blocker
Aldosterone antagonist
Diuretic
Digoxin
64 (53-73)
126 (63.0)
74 (37.0)
124 (62.0)
64 (32.0)
12 (6.0)
132 (66.0)
40 (20.0)
28 (14.0)
134 (67.0)
27 (13.5)
24 (12.0)
15 (7.5)
71 (35.5)
50 (25.0)
43 (21.5)
22 (11.0)
14 (7.0)
60 (30.0)
40 (20.0)
29 (14.5)
27 (13.5)
14 (7.0)
12 (6.0)
18 (9.0)
159 (79.5)
41 (20.5)
152 (76.0)
48 (24.0)
101 (50.5)
58 (29.0)
27 (13.5)
14 (7.0)
194 (97.0)
68 (34.0)
110 (55.0)
165 (82.5)
126 (63.0)
58 (29.0)
Source: authors. aMedian (first and third quartile). LVEF=Left 
ventricular ejection fraction; NYHA=New York Heart Association; 
ACE=Angiotensin-converting enzyme. 
Psychometric analysis
Internal reliability
Cronbach’s alphas coefficients ranged from 0.73 (social 
dimension) to 0.91 (physical dimension and total 
score) in the MLHF-Q, indicating satisfactory level for 
internal consistency. Descriptive analysis and internal 
consistency of the MLHF-Q are shown in Table 2 and 
Supplementary Material Table S1.
Table 2. Descriptive analysis and internal consistency of the 
Minnesota Living with Heart Failure Questionnaire (n=200). 
Quality of 
life
Number 
of items
Median 
(Q1-Q3)a
Range
Cronbach’s 
α
95% CI
Physical 
dimension 8 11 (4-23) 0-40 0.91 0.89-0.93
Emotional 
dimension 5 7 (3-13) 0-24 0.80 0.76-0.85
Social 8 16 (10-22) 0-32 0.73 0.68-0.78
Total score 21 40 (20-55) 0-95 0.91 0.90-0.93
Source: authors. aQ1-Q3=First and third quartile.
Construct validity
The KMO statistic was 0.90, indicating sampling 
adequacy (Supplementary Material Table S2) and 
Bartlett’s test of sphericity was statistically significant 
(chi2 (210)= 2126.20; p=0.000), suggesting that data 
were appropriate to be subjected to a factorial analysis22. 
All items in the first factor were associated to signs and 
symptoms of HF; this factor was identified such as 
physical dimension. The second factor, included four 
items of five items from the original questionnaire, 
and they were related to the patient’s psychological 
response to disease; this factor was recognized as 
the emotional dimension. Finally, three items in the 
third factor were correlated to the patient’s social 
relationships, thus this factor was named the social 
dimension. Then, confirmatory factorial PCA of three 
factors explained 54.03% of total variation in the study 
population, of which 30.6% was explained by the first 
factor, 15.8% the second factor and 7.6% the third 
dimension. Eigenvalue was 6.43 for the physical, 3.31 
for the emotional, and 1.59 for the social dimension 
(Supplementary Material Table S3).
Table 3 shows factorial analysis, five of the 21 items 
demonstrated factor loadings between 0.4 and 0.6; 
four between 0.6 and 0.7; six between 0.7 and 0.8; 
four items had factor loadings >0.8 and, two items 
(14 and 16) did not adequately load (loading <0.4). 
Additionally, in Table 3 we can distinguish physical, 
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emotional and social dimensions. Also, items 1, 8, 9, 
10 (social) and 20 (emotional) have been reclassified in 
physical dimension. Conversely, emotional dimension 
is preserved almost entirely, except for item 20. Finally, 
item 8 could belong to both, the physical and social 
dimension.
Table 3. Factorial principal component analysis with orthogonal varimax rotation (loadings) of the Minnesota Living with Heart 
Failure Questionnaire. 
Item
Factor1 
(Physical)
Factor2 
(Emotional)
Factor3 
(Social)
Uniqueness
1. Swelling in your ankles, legs 0.5120a 0.6223
2. Resting during day 0.7834b 0.3565
3. Walking or climbing stairs difficult 0.8388b 0.2816
4. Working around house difficult 0.8264b 0.2747
5. Away from home difficult 0.7965b 0.3158
6. Sleeping difficult 0.5547b 0.6568
7. Relating to or doing things with friends or family difficult 0.6013b 0.5491
8. Working to earn a living difficult 0.7058a 0.4391a 0.2883
9. Recreational activities difficult 0.6374a 0.4775
10. Sexual activities difficult 0.4471a 0.7653
11. Eating less foods I like 0.6183a 0.5349
12. Shortness of breath 0.6765b 0.4462
13. Fatigue 0.8216b 0.2710
14. Hospitalization ---- ---- ---- 0.7383
15. Medical costs 0.7819a 0.3630
16. Side effects from medications ---- ---- ---- 0.8387
17. Feeling burden to family or friends 0.7972c 0.3314
18. Feeling loss of self-control 0.8719c 0.2252
19. Being worried 0.7854c 0.3146
20. Difficulty concentrating or remembering 0.4947c 0.6825
21. Being depressed 0.7746c 0.3204
Source: authors. aSingle items used in the construction of the overall score (social dimension); bPhysical dimension; cEmotional dimension. 
Regarding Rasch analysis of the total score, the 
average measures of the rating scale of the MLHF-Q 
were ordered, progressing from -0.84 logits for rating 
scale category zero (no impairment) to 0.27 logits for 
rating scale category of five (very much impairment); 
disordered thresholds (response categories not working 
logically) were corrected by combining adjacent 
categories (Supplementary Material Figure S1); the 
result was a 3-point scale that met the criteria for rating 
scale. Eight persons had a ZSTD exceeding the value 
expected and were excluded from the analysis. 
The person separation was 2.56 and reliability 0.87; for 
items these statistics were 5.00 and 0.96, respectively. 
Items 15, 16, 20, 14 and 10 showed fit statistics (Outfit, 
Infit) out of the established range for the analysis; 
statistics are shown in Table 4. In the PCA of residuals, 
21 items and 192 persons explained the 42.0%. In 
the first contrast, we observed 3.3 eigenvalues with 
residuals correlations higher than 0.50. Items 1, 15, 
16 and 17 had a difference in difficulty ≥0.5 logits by 
groups of age with Welch p values under 0.05. There 
was no evidence of uniform DIF by sex groups. After 
removing the five misfit items, the overall fit of the data 
improved, with 47.7% of raw variance explained and 
only two items (6 and 11) maintaining their fit statistics 
above the range. 
In the analysis of physical, emotional and social 
dimensions, disorders of the rating scale were not 
observed, in fact, all analyses were made with the 
original MLHF-Q codification. Social dimension’s 
items explained 44.8% of the variance and had 1.7 
eigenvalues in the first contrast, the residual did not 
present any important correlation. Item 8 (working to 
earn a living difficult) of social dimension had a slightly 
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lower value of the range. The eight items of physical 
dimension presented 2 eigenvalues in the first contrast 
and explained 57.4% of the raw variance; two of the 
items were above and one item was below expected 
range as shown in Table 4. 
Table 4. Severity levels, standard errors, and goodness-of-fit indexes of the 21 MLHF-Q items and by dimensions using Rasch 
analysis (n=192).
Items Description δ (logit)a SE
MNSQ
Infit Outfitb
Total
15 Medical costs -1.04 0.11 1.57 1.91
16 Side effects from medications 0.30 0.11 1.28 1.59
20 Difficulty concentrating or remembering -0.38 0.11 1.13 1.56
14 Hospitalization 1.07 0.13 1.48 1.41
10 Sexual activities difficult -0.34 0.11 1.35 1.33
6 Sleeping difficult 0.09 0.11 1.13 1.20
11 Eat less food you like -1.58 0.12 1.17 1.10
9 Recreational activities difficult -0.40 0.11 1.10 1.09
18 Feeling a loss of self-control 0.49 0.12 1.10 1.07
17 Feeling burden to family or friends 0.63 0.12 1.08 0.96
1 Swelling in your ankles, legs 0.90 0.13 1.01 0.98
19 Being worried -0.09 0.11 1.00 0.99
7 Relating to or doing things with friends or family difficult 0.60 0.12 0.92 0.83
21 Being depressed 0.40 0.12 0.89 0.88
8 Working to earn a living difficult -0.65 0.11 0.81 0.73
3 Walking or climbing stairs difficult -0.43 0.11 0.77 0.72
5 Being away from home difficult 0.14 0.11 0.77 0.66
12 Shortness of breath 0.53 0.12 0.73 0.76
4 Working around house difficult -0.02 0.11 0.73 0.65
2 Resting during day 0.04 0.11 0.60 0.57
13 Fatigue -0.25 0.11 0.57 0.56
Physical      
6 Sleeping difficult -0.04 0.06 1.70 1.88
7 Relating to or doing things with friends or family difficult 0.39 0.07 1.43 1.55
12 Shortness of breath 0.33 0.07 1.07 1.26
5 Being away from home difficult 0.03 0.07 0.95 0.83
4 Working around house difficult -0.05 0.06 0.85 0.81
3 Walking or climbing stairs difficult -0.36 0.06 0.80 0.75
2 Resting during day -0.06 0.06 0.78 0.75
13 Fatigue -0.24 0.06 0.60 0.65
Emotional  
20 Difficulty concentrating or remembering -0.43 0.06 1.72 2.30
17 Feeling burden to family or friends 0.30 0.07 0.93 0.86
19 Being worried -0.19 0.06 0.80 0.77
21 Being depressed 0.09 0.07 0.74 0.64
18 Feeling a loss of self-control 0.23 0.07 0.70 0.62
Social  
10 Sexual activities difficult -0.08 0.05 1.25 1.29
16 Side effects from medications 0.24 0.05 1.10 1.28
14 Hospitalization 0.51 0.06 1.18 1.14
15 Medical costs -0.33 0.05 1.07 1.17
9 Recreational activities difficult -0.08 0.05 0.98 0.93
11 Eat less food you like -0.55 0.05 0.86 0.90
1 Swelling in your ankles, legs 0.47 0.05 0.87 0.82
8 Working to earn a living difficult -0.20 0.05 0.68 0.63
Source: authors. aδ level of severity (higher values indicate higher severity). bExpected range 0.7 - 1.3.   MLHF-Q=Minnesota Living with Heart 
Failure Questionnaire; SE=Standard error; MNSQ=Mean square fit statistic; Infit=Inlier-sensitive fit; Outfit=Outlier-sensitive fit.
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In the emotional dimension, one item presented a severe 
misfit Table 4, the variance explained by these items 
was 54.0% and had 1.7 eigenvalues in the first contrast; 
correlation of -0.51 between items 19 and 20 was 
found. Eliminating item 20 and analyzing the remaining 
four items, all statistics were into the expected values 
(Supplementary Material Table S4) and the variance 
explained improved (Supplementary Material Table 
S5). It was not detected uniform DIF by sex or age 
group in any dimension. Wright maps are presented for 
each dimension evaluated (Supplementary Material 
Figure S2).
Contrast validity
Discriminative capacity of the MLHF-Q subscales and 
for the overall score was observed in age and NYHA 
functional class (p <0.05). Worse HRQoL was observed 
among women than men in the emotional dimension 
(p=0.047). Although higher HRQoL impairment 
was evident in LVEF ≤ 45% compared with LVEF 
>45% patients, it was not statistically significant 
(Supplementary Material Table S6).
Discussion
To the best of our knowledge, the present work is the first 
study that has assessed the psychometric properties of 
the MLHF-Q in a Spanish-speaking population of Latin 
America. We have evaluated the internal consistency, 
construct validity through the two methods (PCA and 
Rasch analysis), and the discriminative capacity of the 
MLHF-Q in outpatients with CHF in Colombia. 
Interpretation of findings
The reliability of subscales and overall MLHF-Q 
showed a Cronbach’s alpha acceptable to excellent, 
with coefficients similar to those in other populations: 
Australia, France, Hungary, Yugoslavia (physical 
dimension α=0.91); Hungary, Poland, Sweden 
(emotional dimension α=0.80); Israel, Italy (social 
dimension α=0.73), and Denmark, Spain, Yugoslavia 
(total score α=0.91)23,26.
Regarding construct validity, we found that the three 
factors explain 47.7% and 54.03% of the overall score 
in the Rasch analysis and PCA, respectively, with 
similar results previously reported by another study27, 
while in other studies the variance explained by these 
three factors has been higher (64.1 to 72%)9,10,19,28. Also, 
we found the following similarities with other authors; 
Heo, et al.27 evidenced that items (1 and 9) were loaded 
on physical dimension and items (14 and 16) presented 
loading <0.4.  Ho, et al.19 showed that item 1 was loaded 
on physical dimension. Finally, Moon, et al.28 found that 
items (1, 9 and 10) were loaded on physical dimension. 
Item 1 (Swelling in your ankles, legs) is part of the 
social dimension (another dimension) from original 
version; however, it has been reported that up two 
thirds of patients admitted with acute HF presented 
hypervolemia signs such as jugular venous distension 
and peripheral edema, typical physiopathological 
manifestations of HF29-30,which support its correlation 
to the physical dimension. On the other hand, 
determine the most plausible dimension for item 10 
(sexual activities difficult) is complicated, due to the 
multifactorial explanation (psychological, emotional, 
physical and medical) of HF patients’ sexual activity31. 
Also, possible explanations for the differences 
found in the factor structure, variance explained, and 
eigenvalues with other authors could be sample size, 
culture, demographics and clinical characteristics, 
among others10,17. 
The MLHF-Q is interpreted by its total score, which 
results of averaging the score of all 21 items. However, 
this assumes that the total score is unidimensional. 
Nevertheless, Rasch analysis for the total score did not 
find evidence of unidimensional functioning. Moreover, 
it demonstrated misfitting of five items (10, 14, 15, 16, 
20), and therefore confirming the existence of some 
problematic items in the composition of the total score. 
Elimination of items has been reported as a solution10,27. 
Exclusion of problematic items in our study improved 
the general fit to the Rasch model. 
Similar findings have been reported by Munyombwe, 
et al.10 who found that several items (7, 8, 10, 14, 16) 
presented misfit. Also, Bilbao, et al.24 reported two 
misfitting items (1 and 10). Considering that misfitting 
items have been identified in a third factor presenting 
the social dimension, as also shown in the current study, 
several authors have suggested to add a third factor to 
the total score9,10,19,23,28. However, it remains a challenge 
to reach a consensus on which of the different social 
factors proposed is the most appropriate and has the 
best psychometric properties, and therefore, future 
studies should examine further and use confirmatory 
techniques. 
Regarding to response categories, we found difficulties 
in distinguishing between the response options very 
little (1) and little (2), or much (4) and very much (5). 
This pattern was also reported by Munyombwe, et al.10, 
who suggests that it could be explained by the sample 
size or an excess of response categories.
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According to the findings of the item-map graphics for 
the subscales, some patients are in the bottom of the 
emotional and physical subscales person-item maps, 
denoting floor effects. This finding is consistent with 
Munyombwe, et al.10, and suggests that those subscales 
need more items to cover all the levels of the underlying 
trait. Nevertheless, some studies have reported either 
floor or ceiling effect in the analysis of total score of 
the MLHF-Q10. 
In relation to other variables that measure different 
stages of disease severity, our results are consistent 
with a priori hypothesis. The MLHF-Q scores clearly 
discriminate between different stages of NYHA 
functional class and age. This has also been observed in 
both observational studies9,11,13, as well as clinical trials, 
where it is the ideal setting for assessing sensitivity to 
change32-34.
Strengths and limitations
The strengths of our study include an adequate sample 
size, as also shown by the KMO statistic. Also, we 
provide complete analyses of the structural validity, 
using both factorial PCA and Rasch analysis. The 
present study has, however, some important limitations 
to consider. First, our study was conducted in a single 
HF center. Accordingly, study results cannot be 
considered a representative description of the HRQoL 
of all Colombia’s HF clinics. Second, the MLHF-Q is 
a self-administered questionnaire and, in our study it 
was applied by a nurse because a high percentage of 
our population had low educational level, and therefore 
it could have affected the measurement of the HRQoL.
Conclusions
In conclusion, we have assessed the content, the internal 
consistency, construct and discriminative capacity of 
the MLHF-Q in patients with CHF from Colombia. We 
have confirmed the three-factor structure of MLHF-Q 
such as previous studies, and satisfactory level for 
internal consistency. Additionally, these results suggest 
that the questionnaire adequately reflects the severity 
of the disease. However further studies are required in 
Colombian population to validate these findings and to 
evaluate the sensitivity to change of the MLHF-Q in 
longitudinal designs.
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Supplementary Material
Supplementary Table S1. Internal consistency of the Minnesota Living with Heart Failure Questionnaire (n=200).
Item Sign
Item-test
correlation
Item-rest
correlation
Average inter-item 
covariance
Alpha
1. Swelling in your ankles, legs
2. Resting during day
3. Walking or climbing stairs difficult
4. Working around house difficult
5. Away from home difficult
6. Sleeping difficult
7. Relating to or doing things with friends or family difficult
8. Working to earn a living difficult
9. Recreational activities difficult
10. Sexual activities difficult
11. Eating less foods I like
12. Shortness of breath
13. Fatigue
14. Hospitalization
15. Medical costs
16. Side effects from medications
17. Feeling burden to family or friends
18. Feeling loss of self-control
19. Being worried
20. Difficulty concentrating or remembering
21. Being depressed
Test scale
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
0.5822
0.7345 
0.7535
0.7907 
0.7732
0.5716
0.6543
0.7733
0.6852
0.4893
0.4451
0.6911
0.7934
0.4095
0.3486
0.4084 
0.5497
0.5369 
0.6079 
0.4493 
0.6208   
0.5341
0.6966
0.7141
0.7561
0.7353
0.5136
0.6091
0.7325
0.6292
0.4180
0.3842
0.6498
0.7627
0.3432
0.2780
0.3454
0.4948
0.4816
0.5555
0.3875
0.5722
1.0813
1.0416
1.0266
1.0169
1.0182
1.0697
1.0611
1.0087
1.0242
1.0811
1.1037
1.0542
1.0300
1.1080
1.1199
1.1108
1.0813
1.0848
1.0655
1.1017
1.0674
1.0646
0.9103
0.9066
0.9059
0.9049
0.9053
0.9107
0.9086
0.9052
0.9080
0.9132
0.9133
0.9078
0.9052
0.9143
0.9157
0.9141
0.9110
0.9113
0.9097
0.9133
0.9094
0.9137
Supplementary Table S2. Kaiser-Meyer-Olkin (KMO) measure of sampling adequacy.
Item KMO
1. Swelling in your ankles, legs
2. Resting during day
3. Walking or climbing stairs difficult
4. Working around house difficult
5. Away from home difficult
6. Sleeping difficult
7. Relating to or doing things with friends or family difficult
8. Working to earn a living difficult
9. Recreational activities difficult
10. Sexual activities difficult
11. Eating less foods I like
12. Shortness of breath
13. Fatigue
14. Hospitalization
15. Medical costs
16. Side effects from medications
17. Feeling burden to family or friends
18. Feeling loss of self-control
19. Being worried
20. Difficulty concentrating or remembering
21. Being depressed
Overall
0.9469 
0.9449
0.8850
0.9479
0.8805
0.9451
0.9522
0.9219
0.9147
0.9334
0.8967
0.9440
0.9132
0.7203
0.7414
0.8842
0.8598
0.8335
0.8543
0.8377
0.8817
0.9004
KMO=Kaiser-Meyer-Olkin.
21
Psychometric properties of the Minnesota Living with Chronic Heart Failure Questionnaire in a Colombian population
Supplementary Table S3. Extraction of factors of the Minnesota Living with Heart Failure Questionnaire (n=200).
Dimension Eigenvalue Difference Proportion Cumulative
Physical 6.43121 3.11483 0.3062 0.3062
Emotional 3.31639 1.71791 0.1579 0.4642
Social 1.59847 . 0.0761 0.5403
Method: principal-component factors; Rotation: orthogonal varimax (Kaiser off); Likelihood Ratio test: independent vs. saturated: chi2(210) = 
2126.20 Prob>chi2 = 0.0000.   
Supplementary Table S4. Standarized residuals variance, eigenvalues in the 1st contrast and general coefficients of correlation 
between residuals (n=192).
Dimension
% Variance by 
measures
Eigenvalues unexplained 
variance in 1st contrast
Coefficients between 
residuals
Physical 57.4 2 All <0.50
Emotional 54.0 1.7 19-20 (-0.51)
Emotional without item 20 59.1 1.7 All <0.50
Social 44.8 1.7 All <0.50
Total 42.0 3.3 19-21 (0.52)
Supplementary Table S5. Severity levels, standard errors, and goodness-of-fit indices of the MLHF-Q emotional dimension 
without item 20 using Rasch analysis (n=192).
Items Description δ (logit) SE
MNSQ
Infit Outfit
17 Feeling burden to family or friends 0.29 0.08 1.21 1.18
21 Being depressed -0.02 0.08 1.02 0.96
19 Being worried -0.45 0.08 0.92 0.88
18 Feeling a loss of self-control 0.19 0.08 0.84 0.89
SE=Standard error; MNSQ=Mean square fit statistic; Infit=Inlier-sensitive fit; Outfit=Outlier-sensitive fit.
Supplementary Table S6. Discriminatory capacity of the Minnesota Living with Heart Failure Questionnaire (n=200).
Variable
Physical Median 
(Q1-Q3)
Emotional Median  
(Q1-Q3)
Social Median        
(Q1-Q3)
Total Median 
(Q1-Q3)
Sex
Women
Men
p-value
Age
>65
≤65
p-value
Functional class NYHA
III-IV
I-II
p-value
LVEF (%)
≤45
>45
p-value
15 (4-26)
10 (3-22)
0.433
18 (6-24)
8 (3-20)
0.002*
27 (21-32)
7 (3-17)
0.000*
18 (8-23)
10 (3-22)
0.146
9 (4-15)
7 (3-12)
0.047*
9 (4-14)
6 (3-12)
0.031*
12 (8-18)
6 (3-10)
0.000*
8 (4-14)
7 (3-12)
0.267
16 (9-23)
16 (10-21)
0.730
17 (12-22)
15 (8-22)
0.182
23 (18-27)
13 (8-20)
0.000*
14 (7-20)
17 (10-22)
0.177
43 (23-58)
35 (19-53)
0.273
45 (27-58)
29 (16-52)
0.005*
61 (53-77)
28 (15-46)
0.000*
45 (23-58)
35 (20-54)
0.556
*=p-value <0.05 Mann-Whitney U test. Q1-Q3=First and third quartile; LVEF=Left ventricular ejection fraction; NYHA=New York Heart 
Association.
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Supplementary Figure S1. Category probability curves.
                 
Supplementary Figure S2. Wright map for emotional, physical and social dimensions of 
the MLHF-Q using Rasch analysis (n=192). Each “#” = 2 people; each “.” = 1 person.
